Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript

Oct. 27, 2022 9:30 PM ETSeagen Inc. (SGEN) StockSGEN
SA Transcripts
153.96K Followers

Seagen Inc. (SGEN) Q3 2022 Earnings Conference Call October 27, 2022 4:30 PM ET

Company Participants

Doug Maffei - Vice President, Investor Relations
Roger Dansey - Interim Chief Executive Officer and Chief Medical Officer
Todd Simpson - Chief Financial Officer
Chip Romp - Executive Vice President, Commercial U.S.

Conference Call Participants

Michael Schmidt - Guggenheim
Andrew Berens - SVB Securities
Jeff Hung - Morgan Stanley
Jay Olson - Oppenheimer
Gregory Renza - RBC Capital Markets
Andy Hsieh - William Blair

Operator

Good day and welcome to the Seagen Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note, today’s event is being recorded. I would now like to turn the conference over to Doug Maffei, Vice President, Investor Relations. Please go ahead.

Doug Maffei

Thank you, operator and good afternoon everyone. I am pleased to welcome you to Seagen’s third quarter 2022 financial results conference call. This afternoon, we issued a press release with our results. The press release and supporting slides are available on our website in the Investors section, Events & Presentations page.

Speakers on today’s call will be Roger Dansey, Interim Chief Executive Officer and Chief Medical Officer; Todd Simpson, Chief Financial Officer; and Chip Romp, Executive Vice President, Commercial U.S. Following our prepared remarks, we will open the line for questions. We aim to keep this call to 1 hour and ask that you limit yourself to one question to give everyone an opportunity to participate in Q&A during our call today.

Today’s conference call will include forward-looking statements regarding future or anticipated events and results, including the company’s 2022 financial outlook, anticipated product sales, revenues, costs and expenses; potential clinical and regulatory milestones, including data readouts and regulatory submissions, potential marketing approvals and commercial performance.

Actual results or developments may differ materially from those

Recommended For You

More on SGEN